Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Co    BMY

Delayed Quote. Delayed  - 10/21 10:01:03 pm
50.02 USD   -0.68%
10/21 BRISTOL MYERS S : U.S. Food and Drug Administration Accepts for Prio..
10/21 BRISTOL MYERS S : Updates Conference Call Dial-in/ID for Third Quart..
10/14 BRISTOL MYERS S : Receives Positive CHMP Opinion for Opdivo (nivolum..
News SummaryMost relevantAll newsSector news 

Bristol-Myers Gets SEC Subpoena In Foreign Bribery Probe

share with twitter share with LinkedIn share with facebook
share via e-mail
04/26/2012 | 07:01pm CEST
   By Peter Loftus 

Drug maker Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) said it has received a subpoena from the U.S. Securities and Exchange Commission as part of an investigation into bribery overseas.

Bristol-Myers said the subpoena received in March seeks information related to sales and marketing practices in "various countries."

The New York-based company said in a quarterly report filed Thursday with the SEC that it was cooperating with the government. A spokeswoman declined comment beyond the information in Thursday's SEC filing.

Bristol-Myers, which sells the anti-clotting drug Plavix, previously disclosed that the SEC was investigating the activities of the company's units in Germany, concerning potential violations of the U.S. Foreign Corrupt Practices Act, or FCPA.

U.S. authorities in recent years have stepped up enforcement of the FCPA, which bars U.S. companies from bribing foreign officials to obtain or retain business. Multinational drug and medical-device makers based in the U.S. have been among the targets of enforcement.

Last year, Johnson & Johnson (>> Johnson & Johnson) agreed to pay nearly $80 million to resolve allegations that it paid bribes to doctors in three European countries, as well as kickbacks to Iraq to illegally obtain business under former leader Saddam Hussein.

Other drug makers--including Pfizer Inc. (>> Pfizer Inc.), Merck & Co. (>> Merck & Co., Inc.) and Eli Lilly & Co. (>> Eli Lilly & Co.)--also have been the subjects of federal inquiries regarding the FCPA.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
10/21 BRISTOL MYERS SQUIBB : U.S. Food and Drug Administration Accepts for Priority Re..
10/21 BRISTOL MYERS SQUIBB : Updates Conference Call Dial-in/ID for Third Quarter 2016..
10/20 BRISTOL MYERS SQUIBB : Opdivo nivolumab Shows Durable Response in Longest Follow..
10/20 BRISTOL MYERS SQUIBB : Presents Results From CheckMate -026, a Phase 3 Study of ..
10/20 BRISTOL MYERS SQUIBB : Patent Issued for Crystalline Forms of N,N-Dicyclopropyl-..
10/20 BRISTOL MYERS SQUIBB : Yervoy ipilimumab Improves Overall Survival in Fully Rese..
10/20 BRISTOL MYERS SQUIBB : Trademark Application for "CESVUNO" Filed
10/20 BRISTOL MYERS SQUIBB : Results From CheckMate-275 Validate Further Study of Opdi..
10/20 BRISTOL MYERS SQUIBB : Opdivo nivolumab Stabilized Patient-reported Outcomes in ..
10/20 BRISTOL MYERS SQUIBB : Safety Data for Lirilumab in Combination with Nivolumab o..
More news
Sector news : Pharmaceuticals - NEC
10/20DJE.ON to Invest $500 Million in Illinois Wind Farm
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake --..
10/19DJAbbott Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJABBOTT LABORATORIES : Labs Swings to Loss After Booking Charge on Mylan Stake
10/19DJPFIZER : J&J Brushes Off Pfizer's Challenge -- WSJ
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
10/21 HERE'S HOW LILLY AND MERCK ARE FARIN : Earnings Out Next Week
10/20 Collaborative Leukemia Trial Orbits Moonshot Initiative
10/19 Mid-stage study of Eiger's hepatitis D candidate underway
10/18 Bristol-Myers Squibb, Another Disappointing Opdivo Test - What Now?
10/18 What's Ailing Allergan's Share Price
Financials ($)
Sales 2016 18 904 M
EBIT 2016 5 007 M
Net income 2016 4 298 M
Debt 2016 1 241 M
Yield 2016 3,10%
P/E ratio 2016 19,60
P/E ratio 2017 17,22
EV / Sales 2016 4,49x
EV / Sales 2017 4,12x
Capitalization 83 576 M
More Financials
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 64,9 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chief Executive Officer & Director
Lamberto Andreotti Chairman
Charles A. Bancroft Chief Financial Officer & Executive Vice President
Francis M. Cuss Chief Scientific Officer & Executive VP
Paul von Autenried Chief Information Officer & Senior Vice President
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.44%310 358
ROCHE HOLDING LTD.-15.88%202 361
NOVARTIS AG-13.36%198 298
PFIZER INC.-0.31%195 193
MERCK & CO., INC.15.87%169 231
More Results